RTS,S malaria vaccine candidate
Malaria vaccine candidate reduces disease over 18 months of follow-up in late-stage study of more than 15,000 infants and young children
Results from ongoing Phase III clinical trial announced
Further results from the Phase III efficacy trial of the RTS,S malaria vaccine candidate were presented on Tuesday, 8 October, at the 6th Multilateral Initiative on Malaria (MIM) Pan-African Malaria Conference in Durban, South Africa. These latest results demonstrated that over 18 months of follow-up, RTS,S was shown to almost halve the number of malaria cases in young children (aged 5-17 months at first vaccination) and to reduce by around a quarter the malaria cases in infants (aged 6-12 weeks at first vaccination).
- Read the press release.
- View the MIM abstract.
- View related resources.
- Read about the Phase III results in 6 to 12-week-olds, released in 2012.
- Read about the Phase III results in 5 to 17-month-olds, released in 2011.